Ameritas Investment Company’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Ameritas Investment Company’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-300	Closed	-$22.1K	–	1676
2021 Q1	$22.1K	Buy	+300	New	+$22.7K	﹤0.01%	1252
2020 Q2	–	Sell	-300	Closed	-$14K	–	1212
2020 Q1	$14K	Buy	+300	New	+$15.6K	﹤0.01%	1113
2019 Q4	–	Sell	-300	Closed	-$14K	–	1303
2019 Q3	$14K	Buy	+300	New	+$15.4K	﹤0.01%	1039
2019 Q1	–	Sell	-814	Closed	-$38K	–	1533
2018 Q4	$38K	Buy	+814	New	+$41.8K	0.01%	657

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACM

Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

PSUF

People's United Financial Bridgeport, Connecticut $3.51B AUM 12.24% 1-Year Est. Return

Ameritas Investment Company's PBE Position: Q2 2021 in Review

Ameritas Investment Company sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2021, closing a stake of 300 shares — an estimated $22.1K sold.

Ameritas Investment Company first reported a position in PBE in Q4 2018 and held it in 4 quarters. The position peaked at $38K in Q4 2018. 94 funds tracked by Wall St. Rank hold PBE as of Q2 2021.

Ameritas Investment Company reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2021 after selling out during the quarter.
Ameritas Investment Company sold 300 Invesco Biotechnology & Genome ETF shares in Q2 2021, an estimated $22.1K.
Ameritas Investment Company first reported a position in Invesco Biotechnology & Genome ETF in Q4 2018 and held it in 4 quarters.
Ameritas Investment Company's Invesco Biotechnology & Genome ETF position peaked at $38K in Q4 2018.
94 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2021.

Based on Ameritas Investment Company's 13F filing for Q2 2021, filed 16 Aug 2021.